Medical Virology is a specialized branch of virology that focuses on the study of viruses and their interactions with the human body, particularly in the context of infectious diseases and public health. It encompasses a wide range of research areas, including viral pathogenesis, epidemiology, diagnosis, treatment, and prevention. Vaccines are a key component of medical virology, as they play a critical role in preventing viral infections and controlling the spread of infectious diseases. Vaccines work by stimulating the body's immune system to recognize and respond to specific viral antigens, priming it to mount a protective immune response upon exposure to the virus.
Medical virologists play a central role in the development and evaluation of vaccines, from initial vaccine design and preclinical testing to clinical trials and post-marketing surveillance. They study the structure and function of viruses to identify potential vaccine targets, such as viral proteins or surface molecules, and develop strategies to induce protective immunity. Vaccines have been developed for a wide range of viral diseases, including measles, mumps, rubella, polio, influenza, hepatitis, human papillomavirus (HPV), and COVID-19. These vaccines have been highly successful in reducing the burden of infectious diseases and preventing outbreaks, saving millions of lives worldwide.
Medical virologists also play a crucial role in vaccine safety monitoring and surveillance, ensuring that vaccines are safe and effective for use in the population. They conduct studies to assess the safety and efficacy of vaccines, monitor adverse events following vaccination, and investigate vaccine failures or breakthrough infections. In addition to vaccine development, medical virologists study the natural history of viral infections, including how viruses spread, replicate, and cause disease in humans. They use advanced diagnostic techniques, such as molecular assays and serological tests, to detect and identify viral pathogens and monitor the progression of viral infections.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States